Home  >  TopNews
you can get e-magazine links on WhatsApp.Click here
Disease Profile + Font Resize -

Boehringer Ingelheim India chips in expertise for better stroke-ready hospitals & advanced drugs

Nandita Vijay, Bengaluru
Thursday, October 29, 2020, 08:00 Hrs  [IST]

Boehringer Ingelheim India has chipped in its expertise for better stroke ready hospitals and advanced drugs in the country. A disease like stroke requires a multi-pronged approach with prevention, treatment as well as awareness strategies in place continuously.

Stroke continues to be a leading cause of disability and death in India, bringing to light the need for an integrated and comprehensive approach to address this growing concern. On the occasion of the World Stroke Day, observed annually on October 29, the company’s global ‘Angels Initiative’ endorsed by the World Stroke Organisation (WSO), European Stroke Organisation (ESO), the European patient organization SAFE and several other National stroke organizations is to assist in improving stroke care across the world.

The strategy is to have better stroke ready hospitals, achieve a sufficient coverage of medical centres with the basic facility of physician- neurologist, CT scan and MRI facility and access to thrombolytic treatment, ensuring that every patient will have access to guideline recommended stroke care, Dr Shraddha Bhure, medical director, Boehringer Ingelheim India, told Pharmabiz.

Since August 2017 with the Angels Initiative implementation in India, we have developed over 200 stroke ready centres. Alongside, we have trained over 2,000 physicians on virtual simulation through body interact tool, CT imaging interpretation training and EMS training. We have well over 3,500 nurses trained on stroke nurse certification, added Dr Bhure.

“Our measures to address this disease remain robust. We are focused on building public awareness and providing comprehensive treatment for acute stroke. We have been the pioneers in this dual approach with our molecule rtPA/Alteplase/Actilyse, the only globally approved drug for use in acute stroke, as thrombolysis/clot dissolution is used by doctors globally in stroke management for well over 25 years. In addition, our Dabigatran etexilate/Pradaxa, was the first NOAC/DOAC/new class of oral anticoagulant in the world to be approved primarily for preventing occurrence of stroke in patients with atrial fibrillation, a cardiac disease that increases the risk of stroke,” stated Sampada Gosavi, director-specialty business, Boehringer Ingelheim India.

A cause of concern is that stroke often goes undiagnosed and even if identified, is not addressed on time. We are dedicated to disseminating scientifically robust information and increasing public awareness related to acute stroke. We have been committed to this objective and have been rolling out multi-channel stroke awareness programs. This has been possible with persistent support from stroke treating physicians, neurologists, health care professionals, the Government of India, administration at hospitals, academic conferences, and think-tank platforms, added Gosavi.
The current COVID-19 pandemic has not made a dent in BI’s unwavering commitment to the cause, as we currently utilise digital tools and technology to ensure our focus on acute stroke remains sharp as ever. As global leaders in this therapy, we recognise the importance of creating better awareness around stroke and its symptoms, to enable patients to reach Stroke Ready Centres within the crucial time window of 4.5 hours. We have leveraged social media platforms like our ACTFAST Facebook page to create greater awareness around stroke and reach the maximum amount of people, she added.


* Name :     
* Email :    
  Website :  
Copyright © 2016 Saffron Media Pvt. Ltd |